Skip to main content
. Author manuscript; available in PMC: 2018 Sep 5.
Published in final edited form as: Nat Chem Biol. 2018 Mar 5;14(4):405–412. doi: 10.1038/s41589-018-0010-y

Figure 4. Antiproliferative effect of selective TRIM24 degradation in acute leukemia.

Figure 4

(a) Immunoblot for TRIM24 and Vinculin following 24 hours of incubation of MOLM-13 cells with the indicated concentrations of dTRIM24. (b) Immunoblot for TRIM24 and Vinculin following treatment of MOLM-13 cells with 2.5 µM dTRIM24 for the indicated incubation times. For a–b, percentages were calculated by normalization of the band intensity to the loading control and relative to DMSO at each timepoint. n=3 independently conducted experiments with one representative experiment shown. (c) Proteomic analysis in MOLM-13 cells treated for 4 hours with DMSO or 2.5 µM of IACS-9571. Fold-change in the abundance of 5897 proteins from IACS-9571 to DMSO treatment versus p-value (t-test; triplicate analysis). (d) As described in (c), with cells treated with 2.5 µM of dTRIM24. (e) Growth over time of MOLM-13 cells treated with 5 µM of indicated compounds over 7 days (values represent means +/− standard deviation, n=3 independently conducted experiments). (f) Induction of apoptosis in MOLM-13 cells indicated by PARP cleavage at 48 hours with dTRIM24, comparable to PARP cleavage induced by treatment with the positive control staurosporine (STS) for 4 hours. n=2 independently conducted experiments with one representative experiment shown. Full immunoblots shown in Supplementary Fig. 10.